Topic: Innovative Payment Models
-
Blueprints for Indication-Specific Pricing
Read More
-
Pharmaceutical Products and Their Value
Read More
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
Read More
-
Abandon Biosimilars as Biologics are Natural Monopolies
Read More
-
Overview of Original Subscription Model and Features of LA and WA Proposals
Read More
-
The “Netflix Model” of Financing Hepatitis C Treatment
Read More
-
Part B Payment for Medicare Drugs
Read More
-
Do High Drug Prices Drive Innovation, Or Hurt It?
Read More